<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68905">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027740</url>
  </required_header>
  <id_info>
    <org_study_id>almond.2013</org_study_id>
    <nct_id>NCT02027740</nct_id>
  </id_info>
  <brief_title>Almond Intervention in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Almond Supplementation on Glycemic and Cardiovascular Risk Factors in Asian Indians in North India With Type 2 Diabetes Mellitus: A 24-week Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetes Foundation, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diabetes Foundation, India</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective cohort study of an almond-enriched diet (within the overall context of
      Asian Indian dietary guidelines) was conducted to test the hypothesis that in patients with
      T2DM almond-enriched balanced diet improves glycemic measures and CVD risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in LDL-c</measure>
    <time_frame>baseline, after six months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>baseline, after six months of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>almond</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>almonds are substituted for visible fat and carbohydrates</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>almond</intervention_name>
    <arm_group_label>almond</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in the age range of 25-65 years

          -  on stable doses of metformin from past 3 months

          -  having HbA1C less than 9%

          -  LDL-c ≥100 mg/dl were recruited

        Exclusion Criteria:

          -  Patients on insulin therapy, plioglitazone, insulin secretagogues, beta blockers or
             steroids or suffering from diabetes for more than 10 years

          -  having high uric acid levels (≥ 8 mg/dl),

          -  with accelerated hypertension (stage 2 hypertension according to JNC guidelines) ,
             hypothyroidism, suffering from acute infection or any debilitating disease or with
             renal failure,

          -  appreciable weight loss (more than 10%) during past 6 months

          -  Patients with known food allergy, lipid altering medication or extraneous factors
             that can affect glycemic or lipid parameters
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fortis Flt Lt Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diabetes Foundation, India</investigator_affiliation>
    <investigator_full_name>Dr Anoop Misra</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
